Extended Data Fig. 2: Response of PDOs to chemotherapy and characterization of MEX3A+ cells in human CRC samples.

a, Viability (ATP quantification) of a collection of human patient derived organoids grown in complete SC medium versus medium lacking EGF and supplemented with active TGFβ1 upon treatment with increasing concentrations of 5FU, Oxaliplatin and SN38. Trend line was calculated using LOESS model. n = 3 technical replicates (independent tissue culture wells). b, Distribution of epithelial CRC cells according to KI67 and LGR5 signatures levels in each individual CRC patient sample. Cells are colored by MEX3A expression c. Stratification of patients according to high or low (split by median) average levels of the signature of Lgr5-high/Mex3a-high cells. P value and HR are adjusted by age, gender, mismatch repair status and AJCC stage using a multivariate statistical model, with no adjustment for multiple comparisons. d. Risk of relapse (log HR) expressed as a continuous variable of the Lgr5-high/Mex3a-high signature (Z-scored). Same covariates as in c were included in the statistical model. No adjustment for multiple comparisons e-f, Analogous analyses to c and d, for the gene expression signature of the Lgr5-high/Mex3a-low population. No adjustment for multiple comparisons. See Supplementary Table 3 for detailed cohort description.